A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

Completed · Early Phase 1

Conditions studied: Hepatocellular Carcinoma (HCC)

In brief

This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.

Key facts

Study ID

NCT01247298

Run by

University of Alabama at Birmingham

People needed

17

Starts

2010-10-01

Expected to finish

2016-12-01

Last updated by the study team

2017-08-21

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis
• Patients meeting all the following criteria will be considered for enrollment:
• Pathologically confirmed HCC -OR
• HCC greater than 2 cm with classic radiographic findings on 2 separate testing modalities, or an HCC greater than 2 cm with a serum alpha feto-protein greater than 200.
• Lesions:
• Single liver lesion: measuring 3 cm to ≤ 8 cm*.
• Multiple liver lesions: ≤ 3 liver lesions, none measuring over 5 cm, provided all lesions are considered for TACE.
• Lesions <3 cm if they are in an unfavorable location for ablation† *The size criteria of hepatic lesions are also subjected to the dose volume constraints for radiotherapy, as described below.
• Patient
• Patient deemed to not candidate or should have refused liver-transplant, surgery or RFA.
• Patient must be a candidate and receive TACE.
• ECOG (Eastern Cooperative Oncology Group) Zubrod Performance Scale = 0-1.
• Age > 19
• Patient should not be pregnant. Women of childbearing potential and male participants must practice adequate contraception.
• Adequate hematological profile and adequate liver functions. Signed informed consent document
• Imaging studies completed at least 60 days prior to study entry. Evaluated by radiation oncologist within 2 weeks prior to study entry.

You may not qualify if…

• Patients presenting with any of the following will not be included in the study:
• Prior invasive malignancies
• Prior radiotherapy to the liver or surrounding areas.
• Systemic therapy using any chemotherapy and/or targeted agents given within 2 weeks prior to TACE, during RT, and / or within 3 weeks following RT
• Severe medical co-morbidities
• INR (international normalized ratio) > 2 times upper level normal
• Uncontrolled or symptomatic clinical ascites
• Major surgical procedure within 3 weeks prior to study entry.
• History of hypersensitivity to chemotherapy agents, contrast material.
• Pregnancy, breast-feeding or planning to become pregnant.
• Treatment with any investigational product in the last 4 weeks before study entry.
• Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
• Patients of Reproductive Potential The patient must not be pregnant or breast-feeding at enrollment in the study. Absence of pregnancy must be demonstrated by serum or urine testing prior to enrollment into the study.
• Female patients of child bearing potential (i.e., ovulating, premenopausal, not surgical sterile) must use a medically accepted contraceptive regimen. Male patients must agree to use a medically approved method of contraception.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.